Adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 4, 2015, Pages 493-498

  Viswanathan, Shilpa ^a   Justice, Amy C ^b,c   Caleb Alexander, G ^a   Brown, Todd T ^a,d   Gandhi, Neel R ^e,f   McNicholl, Ian R ^g   Rimland, David ^f,h   Rodriguez Barradas, Maria C ^i,j   Jacobson, Lisa P ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GILEAD SCIENCES   (United States)

^h ATLANTA VA MEDICAL CENTER   (United States)

ⁱ MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Adherence; Current HAART; HIV RNA suppression; Veterans Health Administration Center

Indexed keywords

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; CONFERENCE PAPER; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; TIME; VIRUS LOAD; BLOOD; HIV INFECTIONS; MEDICATION COMPLIANCE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

EID: 84975307979     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000643     Document Type: Conference Paper

References (26)

1. Althoff KN, Buchacz K, Hall HI, et al; North American AIDS Cohort Collaboration on Research and Design. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med. 2012;157:325-335.
2. Hughes CA, Robinson L, Tseng A, et al. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother. 2009;10:2445-2466.
3. Kobin BA, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45:372-379.
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
5. Nelson M, Girard PM, DeMasi R, et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naïve HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother. 2010;65:1505-1509.
6. westergaard RP, Ambrose BK, Mehta SH, et al. Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J Int AIDS Soc. 2012;15:10.
7. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the national VA health information system. Med Care. 2006;44(suppl 2):S25-S30.
8. Braithwaite RS, Kozal MJ, Chang CCH, et al. Adherence, virologic and immunologic outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007;21:1579-1589.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. USA; 2014. Available at: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl. pdf. Accessed May 2014.
10. Steiner JF, Prochanska AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
11. Steiner JF, Kopesell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records: description and validation. Med Care. 1988;26:814-823.
12. Hanna DB, Hessol NA, Golub ET, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. JAcquir Immune Defic Syndr. 2014;65:587-596.
13. Cooper V, Horne R, Gellaitry G, et al. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study. J Acquir Immune Defic Syndr. 2010;53:369-377.
14. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine and efavirenz for HIV. N Eng J Med. 2006;354:251-260.
15. Cooper V, Horne R, Moyle G, et al; The SwEET Study Group. Simplification with easier emtricitabine and tenofovir (SwEET): results of a 48 week analysis of patients' perceptions of treatment and adherence. Paper presented at: The XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico [abstract].
16. Maggiolo F, Airoldi M, Kleinloog HG, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8:282-292.
17. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily dosing antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58:1297-1307.
18. Choudhary NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171:814-822.
19. Moline JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazana-vir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323-332.
20. Bangsberg D. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
21. Ho MP, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028-3035.
22. Simoni JM, Amico KR, Pearson CR, et al. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008;10:515-521.
23. Malta M, Magnanini MMF, Strathdee SA, et al. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14:731-747.
24. Justice AC, Dombrowski E, Conigliaro J, et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care. 2006;44(suppl 2): S13-S24.
25. Franco RA, Saag MS. when to start antiretroviral therapy: as soon as possible. BMC Med. 2013;11:147.
26. Monitoring HIV Care in the United States. Indicators and Data Systems. Institute of Medicine of the National Academies. USA; 2012. Brief Report. Available at: http://www.iom.edu/;/media/Files/Report% 20Files/2012/Monitoring-HIV-Care-in-the-United-States/MonitoringHIV- rb.pdf Accessed May 2014.